Mechanism of Synergy between Epigallocatechin Gallate and β-Lactams against Methicillin-Resistant Staphylococcus aureus
- 1 June 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (6) , 1737-42
- https://doi.org/10.1128/aac.45.6.1737-1742.2001
Abstract
Compared to MICs (more than 800 microg/ml) of (-)-epigallocatechin gallate (EGCg) against Escherchia coli, MICs of EGCg against methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA) were 100 microg/ml or less. Furthermore, less than 25 microg EGCg per ml obviously reversed the high level resistance of MRSA to all types of tested beta-lactams, including benzylpenicillin, oxacillin, methicillin, ampicillin, and cephalexin. EGCg also induced a supersusceptibility to beta-lactams in MSSA which does not express mecA, encoding penicillin-binding protein 2' (PBP2'). The fractional inhibitory concentration (FIC) indices of the tested beta-lactams against 25 isolates of MRSA were from 0.126 to 0.625 in combination with 6.25, 12.5 or 25 microg of EGCg per ml. However, no synergism was observed between EGCg and ampicillin against E. coli. EGCg largely reduced the tolerance of MRSA and MSSA to high ionic strength and low osmotic pressure in their external atmosphere, indicating damage of the cell wall. Unlike dextran and lipopolysaccharide, peptidoglycan from S. aureus blocked both the antibacterial activity of EGCg and the synergism between EGCg and oxacillin, suggesting a direct binding of EGCg with peptidoglycan on the cell wall. EGCg showed a synergistic effect with DL-cycloserine (an inhibitor of cell wall synthesis unrelated to PBP2') but additive or indifferent effect with inhibitors of protein and nuclear acid synthesis. EGCg did not suppress either PBP2' mRNA expression or PBP2' production, as confirmed by reverse transcription-PCR and a semiquantitative PBP2' latex agglutination assay, indicating an irrelevance between the synergy and PBP2' production. In summary, both EGCg and beta-lactams directly or indirectly attack the same site, peptidoglycan on the cell wall. EGCg synergizes the activity of beta-lactams against MRSA owing to interference with the integrity of the cell wall through direct binding to peptidoglycan.Keywords
This publication has 23 references indexed in Scilit:
- Penicillin‐Binding Protein‐Mediated Resistance in Pneumococci and StaphylococciThe Journal of Infectious Diseases, 1999
- Molecular aspects of methicillin resistance in Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 1994
- Inhibition of the infectivity of influenza virus by tea polyphenolsAntiviral Research, 1993
- Bactericidal catechins damage the lipid bilayerBiochimica et Biophysica Acta (BBA) - Biomembranes, 1993
- SERINE β-LACTAMASES AND PENICILLIN-BINDING PROTEINSAnnual Review of Microbiology, 1991
- Antibacterial and bactericidal activities of tea extracts and catechins against methicillin resistant Staphylococcus aureus.Nippon Saikingaku Zasshi, 1991
- The bactericidal activity of tea and coffeeLetters in Applied Microbiology, 1989
- Penicillin‐binding proteins of β‐lactam‐resistant strains of Staphylococcus aureusFEBS Letters, 1985
- Antioxidative activity of tea leaf catechins.Journal of the agricultural chemical society of Japan, 1985
- Comparison of Techniques for Measurement of in Vitro Antibiotic SynergismThe Journal of Infectious Diseases, 1979